Oncternal Therapeutics is a clinical-stage oncology company that focuses on targets uniquely expressed within cancer cells to develop therapies for rare and common malignancies. The company is advancing two clinical-stage programs: cirmtuzumab, an anti-ROR1 monoclonal antibody, and TK216, a small molecule that inhibits ETS-family transcription factor oncoproteins. It leverages scientific and development expertise and academic collaborations to support its programs. Led by President and CEO James Breitmeyer, M.D., Ph.D., Oncternal closed an $18.4M Series B financing to fund development. The company intends to use the proceeds to further clinical development of cirmtuzumab and TK216 and to advance preclinical development of a new ROR1-targeted antibody-drug conjugate program. Oncternal is based in San Diego, California.

Total raised

$18M

Funding rounds

1

Latest round

Series B

Latest activity

Feb 2017